# P21 Peptide

> P21 is a CNTF-derived peptide that targets neurogenesis, synaptic plasticity, and Alzheimer-model neurotrophic signaling pathways.

Canonical: https://pepflow.app/peptides/p21/

The CNTF Fragment

P21 is a CNTF-derived peptide discussed for neurogenesis and Alzheimer-model biology. It is often presented as a small peptide alternative to larger neurotrophic proteins.

Brain health  Neuroaging biology

Tier D

Evidence Limited

Safety Limited Data

FDA status Not Approved

Last reviewed August 11, 2026 21 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is P21?

P21 is a CNTF-derived peptide discussed for neurogenesis and Alzheimer-model biology. It is often presented as a small peptide alternative to larger neurotrophic proteins.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

The strongest story is preclinical: animal models and mechanism work, not established human treatment.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

Names such as P21 and P021 can appear in adjacent literature; route, formulation, and exact molecule need checking before transferring claims.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

## What P21 is investigated for

P21 evidence is grouped by practical use case and intranasal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Hippocampal neurogenesis and synaptic support Intranasal 28% Limited

P21 is a preclinical neurogenesis and synaptic-support candidate, not a validated cognitive therapy.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

#### Human evidence

Human neurogenesis or cognition outcomes for P21 are not established in the cited literature.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

#### Animal / mechanistic evidence

Mouse-model studies report prevention of dendritic, synaptic, and cognitive deficits with a neurotrophic peptidergic compound.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

### ### Alzheimer-model cognition and pathology Intranasal 26% Limited

The Alzheimer evidence is limited to animal-model cognition and pathology, not clinical disease modification.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

#### Human evidence

Human Alzheimer disease outcome trials for P21 are not established in the cited literature.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

#### Animal / mechanistic evidence

Triple-transgenic and related mouse studies reported effects on amyloid, tau, neurodegeneration, and cognitive deficit endpoints.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

### ### Cognitive enhancement in neurodegeneration models Intranasal 25% Limited

Cognitive enhancement remains a preclinical neurodegeneration-model signal, not a validated human nootropic effect.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20600002/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25255260/>)

#### Human evidence

No controlled human P21 cognition trial is established for neurodegenerative disease or healthy-adult nootropic use.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20600002/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25255260/>)

#### Animal / mechanistic evidence

Mouse studies report learning, memory, neurogenesis, and synaptic-plasticity signals across aged, Alzheimer-model, and injury-model contexts.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20600002/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25255260/>)

### ### Traumatic brain injury model recovery Intranasal 24% Limited

TBI recovery is a model-supported research direction, not a clinical rehabilitation claim.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25255260/>)

#### Human evidence

Human traumatic brain injury studies for P21 have not been established.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25255260/>)

#### Animal / mechanistic evidence

A mild-to-moderate TBI animal study reported neurogenesis and memory-related findings after treatment with the neurotrophic peptide.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/25255260/>)

### ### CDKL5-deficiency disorder model support Intranasal 22% Limited

CDKL5-deficiency support is an early model signal and should not be generalized into a pediatric clinical use claim.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/39592934/>)

#### Human evidence

Human CDKL5-deficiency disorder outcome trials for P21-family peptide mimetics are not established.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/39592934/>)

#### Animal / mechanistic evidence

A CNTF small-molecule peptide mimetic was tested in CDKL5-deficiency in vitro and in vivo models, extending the neurodevelopmental research rationale.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/39592934/>)

## Evidence snapshot

### Overall confidence

Limited

30%

P21/P021 remains a preclinical neurotrophic concept. Human pharmacology, tolerability, and cognitive outcomes are not established.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

10%

### Human evidence

Insufficient

No controlled human outcome evidence establishes P21 for neurogenesis, Alzheimer disease, or cognition.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

25%

### Animal / preclinical

Limited

Animal Alzheimer-model studies support neurogenesis and synaptic-plasticity plausibility, but the evidence remains early.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

25%

### Mechanism support

Limited

P21 is described around CNTF-like signaling, neurogenesis, and synaptic support. The mechanism is a brain-repair hypothesis rather than a validated treatment pathway.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

## Forms & administration

P21 is tracked as an intranasal research-market peptide. It is separate from Semax-style products and from approved neurologic medicines.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>)

Nasal spray

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Intranasal protocols use 200-400 mcg per day. Injectable protocols use about 500 mcg per dose.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>)

### Frequency

Intranasal and injectable protocols are once daily.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>)

### Timing Considerations

Morning is the usual timing.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>)

### Cycle Length

Common cycles run 20-30 days.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>)

[Full P21 dosage guide](<https://pepflow.app/peptides/p21/dosage/>)

## What to expect

### First 1-2 weeks

Intranasal P21 use may feel like subtle changes in focus, memory-task flow, mood, or mental fatigue during consistent routines.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)

### Weeks 4-8

Intranasal cognition-oriented effects may appear as steadier task consistency, mood, sleep rhythm, or perceived learning.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)

### After stopping

Perceived cognitive or mood signals may fade gradually toward baseline after intranasal P21 use ends.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)

## Safety profile

P21 safety is mainly intranasal and neuroactive, with limited human data and product-identity uncertainty.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)

### Common side effects

- Nasal irritation [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)
- Headache [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)
- Sleep disruption [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)

### Cautions

- Preclinical evidence[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)
- Neuroactive combinations[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)
- Product quality[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)

### What we don't know

Human dose-ranging, long-term neurologic safety, reproductive safety, and product consistency remain unclear.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)

## Who P21 is not for

Route-specific avoid and medical-review notes:

- **Pregnancy or breastfeeding**

  Pregnancy or breastfeeding warrants medical review or avoidance for P21.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)
- **Unstable neurologic disease**

  Unstable neurologic disease warrants medical review or avoidance for P21.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)
- **Seizure disorder without clinician review**

  Seizure disorder without clinician review warrants medical review or avoidance for P21.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Stimulants / nootropics**

  Stimulants, high-caffeine products, or nootropic stacks can compound insomnia or overstimulation; this is a theoretical neuroactive caution.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)
- **Sedatives / alcohol**

  Alcohol, sleep aids, or sedating supplements can obscure alertness, coordination, and memory effects; this is a theoretical neuroactive caution.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)
- **Other nasal sprays**

  Decongestant, steroid, or irritating nasal sprays can add local irritation or change intranasal tolerability; this is a route-specific caution.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, P21 has no FDA-approved drug product for the reviewed intranasal route. Research-market supply and compounded preparations are separate from approval; the 503A row names the current compounding bucket.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Intranasal | Not Approved · P21 is not FDA-approved as an intranasal drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) | Not Listed · P21 is not in the current reviewed 503A compounding bucket for the intranasal route; compounding status is separate from FDA drug approval.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Intranasal

FDA drug approval

Not Approved

P21 is not FDA-approved as an intranasal drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

503A compounding

Not Listed

P21 is not in the current reviewed 503A compounding bucket for the intranasal route; compounding status is separate from FDA drug approval.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets.[\[14\]](<https://www.ema.europa.eu/en/medicines>) [\[15\]](<https://products.mhra.gov.uk/>) [\[16\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[17\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat P21 intranasal route as athlete-cleared without sport-specific review.[\[9\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

P21 is framed as a CNTF-derived neurotrophic peptide concept tied to neuronal survival, neurogenesis, dendritic structure, synaptic support, and amyloid or tau biology in animal models. In plain terms, it is a brain-repair hypothesis.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

The route caveat is important because the page tracks intranasal research-market use while key published work includes animal treatment models. Intranasal formulation, brain exposure, and human tolerability would have to be shown before mouse cognition signals become a practical human protocol. That route mismatch is the main reason the mechanism stays preliminary.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

## Research gaps & open questions

What the current literature has not yet settled about P21:

01

No human studies have established how P21 is absorbed and cleared, which doses reach the brain, or what side effects occur.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

02

Randomized human trials need to show whether P21 improves memory, attention, or other cognitive function.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

03

Intranasal formulations need direct studies showing how much P21 crosses the nasal lining and reaches the bloodstream or brain.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

## Common questions

### Is P21 FDA-approved?

No. P21 is not FDA-approved in the U.S. for intranasal drug use, and research-market availability is not FDA approval.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>)

### Does P21 treat Alzheimer disease?

No. Alzheimer-related claims come from animal neurodegeneration models, not established intranasal human treatment evidence.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>)

### Is P21 the same as Cerebrolysin?

No. P21 is a defined CNTF-derived peptide concept, while Cerebrolysin is an injectable peptide mixture.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>)

## Myths & misconceptions

### Myth

Mouse Alzheimer-model results mean it treats Alzheimer disease.

### Reality

Animal models are hypothesis-generating and need human trials.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

### Myth

Intranasal use means brain-specific action.

### Reality

Intranasal delivery can still have variable exposure and local tolerability issues.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

## History & discovery

P21 grew from attempts to capture neurotrophic-factor biology in a smaller peptide-like compound. Its history is preclinical, with Alzheimer-model work shaping most of the current interest. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

Chronic treatment in a triple-transgenic Alzheimer mouse model gave P21 its disease-modifying research story. That milestone mattered because it linked the compound to amyloid, tau, and cognition endpoints.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

Later animal studies emphasized dendritic structure, synaptic deficits, neurodegeneration, and cognitive impairment. They strengthened the preclinical rationale while leaving intranasal human efficacy unresolved.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/25046994/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/28655344/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)

## Published research 21 citations

- [\[1\] **Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice.** FEBS Lett, 2010 Aug 4. animal.](<https://pubmed.ncbi.nlm.nih.gov/20600002/>)
- [\[2\] **Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.** Neurobiol Dis, 2014 Nov. animal.](<https://pubmed.ncbi.nlm.nih.gov/25046994/>)
- [\[3\] **Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound.** Alzheimers Res Ther, 2017 Jun 27. animal.](<https://pubmed.ncbi.nlm.nih.gov/28655344/>)
- [\[4\] **Prevention of Amyloid-beta and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound.** J Alzheimers Dis, 2017. animal.](<https://pubmed.ncbi.nlm.nih.gov/28387677/>)
- [\[5\] **Enhancement of neurogenesis and memory by a neurotrophic peptide in mild to moderate traumatic brain injury.** Neurosurgery, 2015 Feb. animal.](<https://pubmed.ncbi.nlm.nih.gov/25255260/>)
- [\[6\] **Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder.** J Neurodev Disord, 2024 Nov 26. animal.](<https://pubmed.ncbi.nlm.nih.gov/39592934/>)
- [\[7\] **Drugs@FDA/openFDA query for P21** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22P21%22&limit=1>)
- [\[8\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[9\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[10\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[11\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[12\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[13\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[14\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[15\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[16\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[17\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[18\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[19\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[20\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[21\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Neuroactive peptide

**Tier**

D

**Evidence**

30% Limited

**Safety**

Limited Data

**FDA status**

Not Approved

**Intranasal 503A**

Not Listed

**Citations**

[21 citations](<https://pepflow.app/peptides/p21/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- Hippocampal neurogenesis and synaptic support
- Alzheimer-model cognition and pathology
- Cognitive enhancement in neurodegeneration models
- Traumatic brain injury model recovery
- CDKL5-deficiency disorder model support

### Common side effects

- Nasal irritation
- Headache
- Sleep disruption

### Also known as

- P021
- CNTF-derived peptide
- Ciliary neurotrophic factor-derived peptide

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [P21 dosage guide](<https://pepflow.app/peptides/p21/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
